Is MeiraGTx Holdings plc (MGTX) a Buy, Sell, or Hold?
MeiraGTx Holdings plc
NASDAQ:MGTX
$12.44 USD
$0.1 (0.81%)
- Volume
- 1.28M
- Average Volume
- 1.03M
- Market Capitalization
- $1.15B
- P/E Ratio
- -8.41
- Dividend Yield
- 0.00%
- Price Target
- $26.00
- Year High
- $15.35
- Year Low
- $6.62
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.55
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Alexandria Forbes |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | MGTX |
| CUSIP | G59665102 |
| CIK | 0001735438 |
| Web | https://www.meiragtx.com |
| Phone | 646 860 7985 |
| Currency | USD |
| Employees | 409 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -1.51 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.55 |
| Quick Ratio | 0.55 |
| Cash Ratio | 0.41 |
Sales & Book Value
| Annual Sales | $81.39M |
| Price / Sales | 14.44 |
| Cash Flow | -0.03 |
| Price / Cash Flow | -491.70 |
| Price / Book | -17.40 |
Price Target and Rating
| Average Stock Price Forecast | $26.00 |
| High Stock Price Forecast | $26.00 |
| Low Stock Price Forecast | $26.00 |
| Forecast Upside/Downside | -52.15% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 7 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.42 |
| Trailing P/E Ratio | -8.41 |
| PEG Ratio | -0.22 |
| P/E Growth | -0.22 |
| Net Income | $-114.2M |
| Net Margin | -151.12% |
| Pretax Margin | -151.12% |
| Return on Equity | 474.91% |
| Return on Assets | -49.27% |
Financials Score
| AltmanZ Score | -4.20 |
| Piotroski Score | 4.00 |
| Working Capital | -79.93M |
| Total Assets | 244.66M |
| Ebit | -108.53M |
| Market Cap | 1.14B |
| Total Liabilities | 302.78M |
Poll Results
About MeiraGTx Holdings plc (NASDAQ:MGTX) Stock
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinic ... al program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
What This MeiraGTx Insider Sale Might Mean With Two Drug Filings Near
2026-07-12 15:19:49
Stuart Naylor liquidated 27,659 shares for $409,000 on July 7, 2026, at a weighted average price of $14.80 per share. The transaction resulted in a 4% reduction of the insider's total direct equity holdings in the company.
MeiraGTx (MGTX) Moves 5.5% Higher: Will This Strength Last?
2026-07-08 10:51:16
MeiraGTx (MGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
2026-07-07 07:30:00
LONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced that it has entered into an agreement with Oberland Capital Management LLC (Oberland Capital) for an investment of up to $400 million in the Company, including up to $375 million in non-dilutive capital for capped royalty payments on certain products and up to $25 million in equity.
MeiraGTx: The Market Is Missing The Manufacturing Pivot
2026-06-29 08:27:06
MeiraGTx is evolving into a late-stage, manufacturing-enabled genetic medicine company with multiple near-term regulatory catalysts. MGTX's robust manufacturing infrastructure and targeted therapies, such as Bota-vec and AAV2-hAQP1, position it for commercial inflection without mass-market commercialization burdens. Recent equity raise and anticipated milestone payments extend MGTX's cash runway through 2H 2028, supporting execution of late-stage programs.
MeiraGTx Holdings plc (MGTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
2026-06-05 16:32:55
MeiraGTx Holdings plc (MGTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
2026-05-15 04:30:45
MeiraGTx Holdings plc (MGTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-05-14 16:30:00
LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee of the Company's Board of Directors approved equity awards to Penny Fleck in connection with her employment with the Company as Chief Development Officer. The equity awards were granted as an inducement material to the new employee entering employment with MeiraGTx in accordance with Nasdaq Listing Rule 5635(c)(4).
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Lags Revenue Estimates
2026-05-14 10:10:25
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.51 per share a year ago.
Frequently Asked Questions
-
What is the current MeiraGTx Holdings plc (MGTX) stock price?
-
MeiraGTx Holdings plc(NASDAQ:MGTX) stock price is $12.44 in the last trading session. During the trading session, MGTX stock reached the peak price of $15.35 while $6.62 was the lowest point it dropped to. The percentage change in MGTX stock occurred in the recent session was 0.81% while the dollar amount for the price change in MGTX stock was $0.1.
-
MGTX's industry and sector of operation?
-
The NASDAQ listed MGTX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of MGTX?
-
Alexandria Forbes | Chief Executive Officer, President & Director
David Rubinstein | Senior Vice President of Business Development
Michel Michaelides | Head of Clinical Ophthalmology
Robert K. Zeldin | Chief Medical Officer
Stuart Naylor | Chief Scientific Officer of Ophthalmology -
How many employees does MGTX have?
-
Number of MGTX employees currently stands at 409. MGTX operates from 430 East 29th Street, New York City, NY 10016, US.
-
Link for MGTX official website?
-
Official Website of MGTX is: https://www.meiragtx.com
-
How do I contact MGTX?
-
MGTX could be contacted at phone #646 860 7985 and can also be accessed through its website. MGTX operates from 430 East 29th Street, New York City, NY 10016, US.
-
How many shares of MGTX are traded daily?
-
The average number of MGTX shares traded daily for last 3 months was 1.03M.
-
What is the market cap of MGTX currently?
-
The market value of MGTX currently stands at $1.15B with its latest stock price at $12.44